AstraZeneca reported solid growth in the top-line, although profitability (at the reported level) fell short of the street’s expectations. Top-line was driven by broad-based growth across the franchise (barring some mature products), led by oncology. Emerging Markets engineered this robust performance, mitigating the deceleration in Europe. Under-performing profitability was a factor of higher sales and marketing investments on new drugs. FY 2019 guidance was reiterated.
29 Apr 2019
Oncology and China drive a solid quarter but profitability limps
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oncology and China drive a solid quarter but profitability limps
AstraZeneca PLC (AZN:LON) | 11,288 4515.2 0.4% | Mkt Cap: 174,990m
- Published:
29 Apr 2019 -
Author:
Kamla Singh -
Pages:
3
AstraZeneca reported solid growth in the top-line, although profitability (at the reported level) fell short of the street’s expectations. Top-line was driven by broad-based growth across the franchise (barring some mature products), led by oncology. Emerging Markets engineered this robust performance, mitigating the deceleration in Europe. Under-performing profitability was a factor of higher sales and marketing investments on new drugs. FY 2019 guidance was reiterated.